A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs B 701 (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- 26 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2017 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.